JP2023116789A5 - - Google Patents

Download PDF

Info

Publication number
JP2023116789A5
JP2023116789A5 JP2023102138A JP2023102138A JP2023116789A5 JP 2023116789 A5 JP2023116789 A5 JP 2023116789A5 JP 2023102138 A JP2023102138 A JP 2023102138A JP 2023102138 A JP2023102138 A JP 2023102138A JP 2023116789 A5 JP2023116789 A5 JP 2023116789A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
seq
lymphoma
composition according
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023102138A
Other languages
English (en)
Japanese (ja)
Other versions
JP7523084B2 (ja
JP2023116789A (ja
Filing date
Publication date
Priority claimed from JP2021067477A external-priority patent/JP7092317B2/ja
Application filed filed Critical
Publication of JP2023116789A publication Critical patent/JP2023116789A/ja
Publication of JP2023116789A5 publication Critical patent/JP2023116789A5/ja
Priority to JP2024107834A priority Critical patent/JP7800872B2/ja
Application granted granted Critical
Publication of JP7523084B2 publication Critical patent/JP7523084B2/ja
Priority to JP2025266852A priority patent/JP2026062750A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023102138A 2017-10-27 2023-06-22 抗ガレクチン－９抗体及びその使用 Active JP7523084B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024107834A JP7800872B2 (ja) 2017-10-27 2024-07-04 抗ガレクチン－９抗体及びその使用
JP2025266852A JP2026062750A (ja) 2017-10-27 2025-12-19 抗ガレクチン－９抗体及びその使用

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201762578111P 2017-10-27 2017-10-27
US62/578,111 2017-10-27
US201862665175P 2018-05-01 2018-05-01
US62/665,175 2018-05-01
US201862736317P 2018-09-25 2018-09-25
US62/736,317 2018-09-25
JP2021067477A JP7092317B2 (ja) 2017-10-27 2021-04-13 抗ガレクチン－９抗体及びその使用
JP2022092009A JP7307443B2 (ja) 2017-10-27 2022-06-07 抗ガレクチン－９抗体及びその使用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022092009A Division JP7307443B2 (ja) 2017-10-27 2022-06-07 抗ガレクチン－９抗体及びその使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024107834A Division JP7800872B2 (ja) 2017-10-27 2024-07-04 抗ガレクチン－９抗体及びその使用

Publications (3)

Publication Number Publication Date
JP2023116789A JP2023116789A (ja) 2023-08-22
JP2023116789A5 true JP2023116789A5 (https=) 2023-09-27
JP7523084B2 JP7523084B2 (ja) 2024-07-26

Family

ID=66246040

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2019569320A Active JP6873445B2 (ja) 2017-10-27 2018-10-29 抗ガレクチン−９抗体及びその使用
JP2021067477A Active JP7092317B2 (ja) 2017-10-27 2021-04-13 抗ガレクチン－９抗体及びその使用
JP2022092009A Active JP7307443B2 (ja) 2017-10-27 2022-06-07 抗ガレクチン－９抗体及びその使用
JP2023102138A Active JP7523084B2 (ja) 2017-10-27 2023-06-22 抗ガレクチン－９抗体及びその使用
JP2024107834A Active JP7800872B2 (ja) 2017-10-27 2024-07-04 抗ガレクチン－９抗体及びその使用
JP2025266852A Pending JP2026062750A (ja) 2017-10-27 2025-12-19 抗ガレクチン－９抗体及びその使用

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2019569320A Active JP6873445B2 (ja) 2017-10-27 2018-10-29 抗ガレクチン−９抗体及びその使用
JP2021067477A Active JP7092317B2 (ja) 2017-10-27 2021-04-13 抗ガレクチン－９抗体及びその使用
JP2022092009A Active JP7307443B2 (ja) 2017-10-27 2022-06-07 抗ガレクチン－９抗体及びその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024107834A Active JP7800872B2 (ja) 2017-10-27 2024-07-04 抗ガレクチン－９抗体及びその使用
JP2025266852A Pending JP2026062750A (ja) 2017-10-27 2025-12-19 抗ガレクチン－９抗体及びその使用

Country Status (14)

Country Link
US (5) US10344091B2 (https=)
EP (2) EP3625263B8 (https=)
JP (6) JP6873445B2 (https=)
KR (1) KR102162129B1 (https=)
CN (2) CN111511765B (https=)
AU (3) AU2018355588C1 (https=)
CA (1) CA3080120C (https=)
DK (1) DK3625263T3 (https=)
ES (1) ES3032734T3 (https=)
IL (4) IL280648B2 (https=)
PT (1) PT3625263T (https=)
SG (1) SG11202003652QA (https=)
WO (1) WO2019084553A1 (https=)
ZA (3) ZA202002246B (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3080120C (en) 2017-10-27 2023-11-21 New York University Anti-galectin-9 antibodies and uses thereof
CN111256416B (zh) * 2018-11-30 2025-09-09 海尔智家股份有限公司 风冷冰箱
AU2020247993A1 (en) * 2019-03-25 2021-11-18 New York University Anti-Galectin-9 antibodies and uses thereof
JP7581238B2 (ja) * 2019-05-01 2024-11-12 ニューヨーク・ユニバーシティ 抗ガレクチン９抗体およびその使用
WO2020237320A1 (en) * 2019-05-31 2020-12-03 The Council Of The Queensland Institute Of Medical Research Anti-gal9 immune-inhibiting binding molecules
US20220235135A1 (en) * 2019-05-31 2022-07-28 The Council Of The Queensland Institute Of Medical Research Activating anti-gal9 binding molecules
CN114026223A (zh) * 2019-06-24 2022-02-08 芬欧汇川集团 包含位于纳米原纤纤维素水凝胶中的真核细胞的可移植细胞组合物、其制备方法和纳米原纤纤维素的用途
US12559559B2 (en) 2019-07-11 2026-02-24 Dana-Farber Cancer Institute, Inc. Targeting Galectin-9 as a therapeutic strategy for T-cell exhaustion in T-cell acute lymphoblastic leukemia
US20220332832A1 (en) * 2019-08-01 2022-10-20 New York University Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics
JP7840842B2 (ja) * 2019-08-14 2026-04-06 アントレラ セラピューティクス インコーポレイテッド Ｌｒｐ５タンパク質に結合する抗体および使用方法
CN120647763A (zh) * 2020-01-07 2025-09-16 高诚生物医药公司 抗半乳糖凝集素-9抗体及其用途
US20230295564A1 (en) * 2020-07-23 2023-09-21 Emory University Galectin-9 Specific Binding Agents for Use in Treating Cancer
WO2022031680A1 (en) * 2020-08-04 2022-02-10 Exelixis, Inc. Cd47 binding agents and uses thereof
CN116390939A (zh) * 2020-08-04 2023-07-04 埃克塞里艾克西斯公司 多重特异性结合剂及其用途
US20230303699A1 (en) * 2020-08-04 2023-09-28 Exelixis, Inc. Pd-l1 binding agents and uses thereof
US20240287195A1 (en) * 2020-10-26 2024-08-29 Puretech Lyt, Inc. Anti-galectin-9 antibodies and uses thereof in the treatment of ocular melanoma
WO2022109299A1 (en) * 2020-11-20 2022-05-27 New York University Anti-galectin-9 antibodies and therapeutic uses thereof
US20240043543A1 (en) * 2020-11-20 2024-02-08 New York University Anti-galectin-9 antibodies and therapeutic uses thereof
EP4297785A4 (en) * 2021-02-26 2025-01-22 New York University COMPOSITIONS AND METHODS USING ANTIBODIES FOR BINDING TO COVALENT PEPTIDE CONJUGATES
US20240190970A1 (en) * 2021-04-30 2024-06-13 Puretech Lyt, Inc. Anti-galectin-9 antibodies and therapeutic uses thereof
CA3217833A1 (en) * 2021-04-30 2022-11-03 Puretech Lyt, Inc. Combination of anti-galectin-9 antibodies and chemotherapeutics for use in cancer therapy
US20240279331A1 (en) * 2021-06-11 2024-08-22 The Regents Of The University Of California Antibodies that stimulate nk cell-mediated cytotoxicity
US20250018038A1 (en) * 2021-10-06 2025-01-16 The University Of Chicago Survivin targeting polypeptides for detection and treatment of cancer
EP4450073A4 (en) * 2021-12-16 2025-11-26 Louis Pasteur Center For Medical Res Intestinal tumor suppressor, PGE2 production inhibitor and IL-22BP production promoter
WO2023245021A2 (en) * 2022-06-14 2023-12-21 Invenra Inc. Multispecific binding agents that target cd25 and/or ctla4 and uses thereof
KR20250029919A (ko) * 2022-06-29 2025-03-05 퓨어테크 엘와이티, 아이엔씨. 갈렉틴-9를 억제하는 항체를 사용한 혈액학적 악성종양의 치료
US12599209B2 (en) * 2023-02-16 2026-04-14 Dongguan Casekey Industry Co., Ltd Card fixation assembly for card holder and card holder
EP4724490A2 (en) 2023-06-12 2026-04-15 Amgen Inc. Lymphotoxin beta receptor agonist binding proteins
WO2025014933A1 (en) * 2023-07-10 2025-01-16 Northwestern University Targeting tim-3 in mapk-driven glioma
WO2025085792A1 (en) * 2023-10-19 2025-04-24 Puretech Lyt, Inc. Treatment of hematological malignancies with antibodies inhibiting galectin-9
WO2025129249A1 (en) * 2023-12-22 2025-06-26 Commonwealth Scientific And Industrial Research Organisation Identifying sequence functionality

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
CA2489769A1 (en) 1989-03-21 1990-10-04 Philip L. Felgner Expression of exogenous polynucleotide sequences in a vertebrate
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
AU648261B2 (en) 1989-08-18 1994-04-21 Novartis Vaccines And Diagnostics, Inc. Recombinant retroviruses delivering vector constructs to target cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ZA911974B (en) 1990-03-21 1994-08-22 Res Dev Foundation Heterovesicular liposomes
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
EP1820858B1 (en) 1991-03-01 2009-08-12 Dyax Corporation Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
DE69233013T2 (de) 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
EP0552108B1 (en) 1992-01-17 1999-11-10 Lakowicz, Joseph R. Energy transfer phase-modulation fluoro-immunoassay
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0650370A4 (en) 1992-06-08 1995-11-22 Univ California METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES.
CA2137361A1 (en) 1992-06-10 1993-12-23 W. French Anderson Vector particles resistant to inactivation by human serum
SE9201984D0 (sv) 1992-06-29 1992-06-29 Pharmacia Biosensor Ab Improvement in optical assays
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
EP1024198A3 (en) 1992-12-03 2002-05-29 Genzyme Corporation Pseudo-adenoviral vectors for the gene therapy of haemophiliae
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
PT695169E (pt) 1993-04-22 2003-04-30 Skyepharma Inc Lipossomas multivesiculares de ciclodextrina encapsulando compostos farmacologicos e metodos para a sua utilizacao
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
DK0814154T3 (da) 1993-09-15 2009-08-31 Novartis Vaccines & Diagnostic Rekombinante alfavirusvektorer
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
AU687117B2 (en) 1993-10-25 1998-02-19 Canji, Inc. Recombinant adenoviral vector and methods of use
AU686277B2 (en) 1993-11-16 1998-02-05 Pacira Pharmaceuticals, Inc. Vesicles with controlled release of actives
DE69535669T2 (de) 1994-05-09 2008-12-04 Oxford Biomedica (Uk) Ltd. Retrovirale vektoren mit verminderter rekombinationsrate
AU4594996A (en) 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
WO1997042338A1 (en) 1996-05-06 1997-11-13 Chiron Corporation Crossless retroviral vectors
ATE332368T1 (de) 1997-01-21 2006-07-15 Gen Hospital Corp Selektion von proteinen mittels rns-protein fusionen
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
WO2000053211A2 (en) 1999-03-09 2000-09-14 University Of Southern California Method of promoting myocyte proliferation and myocardial tissue repair
AU2002214256B2 (en) 2000-11-01 2007-07-12 Galpharma Co., Ltd. Agent for detecting cancer's ability to metastasize
DK2093286T3 (da) 2001-10-01 2013-05-13 Dyax Corp Flerkædede, eukaryote displayvektorer og anvendelser deraf
JP2004244411A (ja) * 2003-01-24 2004-09-02 Galpharma Co Ltd ガレクチン９含有医薬
US20060134119A1 (en) * 2003-01-24 2006-06-22 Mitsuomi Hirashima Drugs containing galectin 9
EP2591786B1 (en) 2003-10-16 2017-04-12 Cancure Limited Immunomodulating compositions and uses therefor
CN101120021A (zh) 2004-12-31 2008-02-06 基因技术公司 结合br3的多肽及其用途
EP1973951A2 (en) 2005-12-02 2008-10-01 Genentech, Inc. Binding polypeptides with restricted diversity sequences
CN101977934B (zh) 2008-01-18 2014-09-17 健泰科生物技术公司 用于靶向k63连接的多聚遍在蛋白的方法和组合物
ES2337224B1 (es) 2008-06-11 2011-02-17 Consejo Superior De Investigaciones Cientificas (Csic) (40%) Anticuerpo anti-dectin-1 humano, hibridoma productor de dicho anticuerpo y sus aplicaciones.
MX2011000655A (es) 2008-07-18 2011-03-21 Oragenics Inc Composiciones para la deteccion y tratamiento de cancer colorrectal.
WO2011159877A2 (en) 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
WO2012064836A1 (en) 2010-11-10 2012-05-18 Genentech, Inc. Methods and compositions for neural disease immunotherapy
CA2820642A1 (en) 2010-12-09 2012-06-14 Galpharma Co., Ltd. Galectin-9-secreting cell, and production method and use of the same
US20140234320A1 (en) 2011-06-20 2014-08-21 La Jolla Institute For Allergy And Immunology Modulators of 4-1bb and immune responses
WO2013056352A1 (en) 2011-10-19 2013-04-25 University Health Network Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
US20140378531A1 (en) 2012-02-01 2014-12-25 New York University Inhibition of pattern recognition receptors in pancreatic cancer treatment using tlr inhibitors
US10966998B2 (en) 2013-09-05 2021-04-06 The Johns Hopkins University Cancer therapy via a combination of epigenetic modulation and immune modulation
JP2017518737A (ja) 2014-04-21 2017-07-13 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ＳＹＫ標的治療薬のための抗ｐＳＹＫ抗体分子及びその使用
FR3021970B1 (fr) * 2014-06-06 2018-01-26 Universite Sciences Technologies Lille Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs
WO2016008005A1 (en) * 2014-07-14 2016-01-21 The Council Of The Queensland Institute Of Medical Research Galectin immunotherapy
AU2015316991B2 (en) 2014-09-16 2021-04-01 Innate Pharma Neutralization of inhibitory pathways in lymphocytes
WO2016061504A2 (en) * 2014-10-17 2016-04-21 The University Of Chicago Recombinant antibodies that recongnize the c-terminal domains of ebola virus nucleoprotein
US10837966B2 (en) 2014-11-04 2020-11-17 Dana-Farber Cancer Institute, Inc. Anti-galectin antibody biomarkers predictive of anti-immune checkpoint and anti-angiogenesis responses
US20160209425A1 (en) 2015-01-16 2016-07-21 New York University Use of dectin-1 activators for treatment of liver disorders
US10294294B2 (en) 2015-09-10 2019-05-21 Albert Einstein College Of Medicine Synthetic antibodies to BAX and uses thereof
WO2017202962A1 (en) 2016-05-24 2017-11-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd)
EP3490568A4 (en) 2016-07-29 2020-04-15 New York University TREATING SOLID TUMORS BY TARGETING DECTIN-1 SIGNALING
US20190248920A1 (en) 2016-09-23 2019-08-15 Csl Limited Coagulation factor binding proteins and uses thereof
CA3080120C (en) 2017-10-27 2023-11-21 New York University Anti-galectin-9 antibodies and uses thereof
US20210315909A1 (en) 2018-07-11 2021-10-14 Arrys Therapeutics, Inc. Polymorphic compounds and uses thereof
AU2020247993A1 (en) 2019-03-25 2021-11-18 New York University Anti-Galectin-9 antibodies and uses thereof
JP7581238B2 (ja) 2019-05-01 2024-11-12 ニューヨーク・ユニバーシティ 抗ガレクチン９抗体およびその使用

Similar Documents

Publication Publication Date Title
JP2023116789A5 (https=)
US11155628B2 (en) Antigen binding proteins that bind c-Met
JP2011505386A5 (https=)
JP5856073B2 (ja) Ｒｏｎ結合構築体およびその使用方法
JP7000322B2 (ja) 抗ｌａｇ３抗体および抗原結合性フラグメント
US20210330787A1 (en) Antigen Binding Proteins That Bind PD-L1
JP2020529863A5 (https=)
HRP20150443T1 (hr) Djelotvorne tvari koje se vežu za notch i njihovi antagonisti te postupci njihove uporabe
US20140294827A1 (en) Fully Human Antibodies that Bind to VEGFR2
US9346890B2 (en) Antigen binding proteins that bind ErbB3
US20170218066A1 (en) Antigen binding proteins that bind pd-l1
JP2021524256A5 (https=)
JP2009528263A5 (https=)
HRP20201085T1 (hr) Humanizirana, mišja ili himerna anti-cd47 monoklonalna antitijela
US10717779B2 (en) Methods for blocking an interaction between notch-1 and delta-like 4 (DLL-4) by administering a DDL-4 antibody
RU2017123549A (ru) Антитела, нацеленные на антиген созревания в-клеток, и способы их применения
JP2013506687A5 (https=)
CN111148535A (zh) 治疗实体癌和血液癌的组合疗法
RU2013158624A (ru) Антитело к cxcr4 с эффекторными функциями и его применение для лечения рака
JP2015518827A5 (https=)
JP2023528416A5 (https=)
IL304295B1 (en) A bispecific antibody with a heterodimeric form with a natural antibody structure ANTI-PD-L1/ANTI-4-1BB and its preparation
CN110540592A (zh) 结合axl蛋白的抗体及其应用
CN107148282A (zh) 结合cxcr3的抗原结合蛋白
EP2830663A2 (en) Fully human antibodies that bind to vegfr2